| 王 凤,邓洪滨,邓立力.TP53、EGFR共突变对NSCLC治疗的影响及对预后预测作用的进展[J].中国肿瘤,2019,28(6):445-449. |
| TP53、EGFR共突变对NSCLC治疗的影响及对预后预测作用的进展 |
| Impact of TP53 and EGFR Mutations on Treatment and Prognosis of Non-small Cell Lung Cancer |
| 投稿时间：2019-03-14 |
| DOI：10.11735/j.issn.1004-0242.2019.06.A009 |
|
 |
| 中文关键词: TP53 肺肿瘤 EGFR 共突变 |
| 英文关键词:TP53 lung neoplasms EGFR co-mutation |
| 基金项目: |
|
| 摘要点击次数: 1653 |
| 全文下载次数: 414 |
| 中文摘要: |
| 摘 要：随着二代基因检测技术的发展，人们发现与单个基因突变相比，多个体细胞共突变已被证明与预后较差有关。在这些共突变中，TP53突变最常见，但被认为是不可用药的靶点。近年来对TP53突变的预测价值进行了深入研究，由于结果不一致，尚未达到临床应用。本篇综述通过对近几年国内外关于TP53抑癌基因与EGFR共突变对非小细胞肺癌（non-small cell lung cancer，NSCLC）治疗及预后的影响进行小结，为EGFR伴随TP53突变NSCLC的靶向治疗提供新的思路。 |
| 英文摘要: |
| Abstract：With the development of second-generation gene detection technology，it has been found that multiple somatic gene mutations are associated with poorer prognosis than single gene mutations. Among multiple gene mutations，the mutations of tumor suppressor gene TP53 are the most common. But TP53 has not been considered as a therapeutic target for anti-cancer drugs and its prognostic value for cancer has been controversial. In this review，we summarize the impact of co-mutated TP53 and EGFR genes on the treatment and prognosis of non-small cell lung cancer(NSCLC)，which may provide new ideas for the targeted therapy and prognosis of patients with NSCLC. |
|
在线阅读
查看全文 查看/发表评论 下载PDF阅读器 |
|
|
|